Pharmacological Foundations of Parkinson's Disease: From Mechanisms to Clinical Practice provides a comprehensive guide on the pharmacological treatment of Parkinson's Disease, offering students and clinicians a combination of foundational knowledge and advanced clinical insights. The book bridges theoretical concepts with real-world clinical scenarios and equips readers with the tools necessary to effectively manage Parkinson's Disease in practice. Offering a detailed review of symptoms, treatment gaps, and emerging therapies, this book delves into the pathogenesis the disease, along with dopaminergic treatments and management of motor and non-motor symptoms.
Providing updates on emerging therapies, including innovative treatment approaches, this book serves as a valuable reference for continuous learning and staying current with evolving practices and research in Parkinson's Disease management.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Dedication - p. v 7. Contributors - p. xix 8. Preface - p. xxiii 9. Acknowledgments - p. xxv 10. Section I. Foundations and pharmacological principles - p. S1 11. Chapter 1. Zebrafish models provide insight into the biological classification of Parkinson's disease - p. 3 12. Chapter 2. Parkinson's disease pathogenesis: From molecular insights to novel therapies - p. 41 13. 2.1 Molecular and cellular mechanisms underlying Parkinson's disease (PD) - p. 41 14. 2.2 Genetic and epigenetic modulators of Parkinson's disease - p. 46 15. 2.3 Neurotransmitter imbalance and circuitry dysfunction in parkinson's disease - p. 54 16. 2.4 Standard pharmacotherapy: Advances, challenges, and optimization - p. 58 17. 2.5 Disease-modifying and neuroprotective strategies - p. 62 18. 2.6 Emerging technologies and future perspectives - p. 73 19. Chapter 3. Cultural and regional considerations in Parkinson’s pharmacotherapy - p. 97 20. Chapter 4. The tango of Parkinson's treatment: Patients, science and the ryhthm of hope - p. 123 21. Chapter 5. Environmental neurotoxins, circadian rhythms and their pharmacological antagonists in Parkinson's disease - p. 141 22. Chapter 6. Oral bacteriome dysbiosis and mechanisms in cognitive impairment among older people and Parkinson's disease: A systematic review - p. 171 23. Chapter 7. Pharmacokinetics and pharmacodynamics in Parkinson's disease - p. 195 24. Section II. Established pharmacotherapies - p. S2 25. Chapter 8. Dopaminergic treatments for Parkinson's disease: Seeing the unseen - p. 235 26. Chapter 9. Catechol-o-methyl-transferase (COMT) inhibitors: Present problems and relevance of the new ones - p. 265 27. Chapter 10. Non-dopaminergic therapies for Parkinson's disease - p. 275 28. Chapter 11. Management of motor symptoms - p. 289 29. Chapter 12. Non-motor symptoms of parkinson's disease and their pharmacological management - p. 319 30. Chapter 13. Clinical case studies and practical applications - p. 345 31. Section III. Adjunctive and advanced therapies - p. S3 32. Chapter 14. Emergent therapeutic agents in the treatment of Parkinson's disease - p. 363 33. Chapter 15. Future directions in Parkinson's disease pharmacotherapy - p. 391 34. Chapter 16. Pioneering the next generation therapies in Parkinson's disease - p. 427 35. Index - p. 455
Pharmacological Foundations of Parkinson's Disease: From Mechanisms to Clinical Practice provides a comprehensive guide on the pharmacological treatment of Parkinson's Disease, offering students and clinicians a combination of foundational knowledge and advanced clinical insights. The book bridges theoretical concepts with real-world clinical scenarios and equips readers with the tools necessary to effectively manage Parkinson's Disease in practice. Offering a detailed review of symptoms, treatment gaps, and emerging therapies, this book delves into the pathogenesis the disease, along with dopaminergic treatments and management of motor and non-motor symptoms.
Providing updates on emerging therapies, including innovative treatment approaches, this book serves as a valuable reference for continuous learning and staying current with evolving practices and research in Parkinson's Disease management.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Dedication - p. v 7. Contributors - p. xix 8. Preface - p. xxiii 9. Acknowledgments - p. xxv 10. Section I. Foundations and pharmacological principles - p. S1 11. Chapter 1. Zebrafish models provide insight into the biological classification of Parkinson's disease - p. 3 12. Chapter 2. Parkinson's disease pathogenesis: From molecular insights to novel therapies - p. 41 13. 2.1 Molecular and cellular mechanisms underlying Parkinson's disease (PD) - p. 41 14. 2.2 Genetic and epigenetic modulators of Parkinson's disease - p. 46 15. 2.3 Neurotransmitter imbalance and circuitry dysfunction in parkinson's disease - p. 54 16. 2.4 Standard pharmacotherapy: Advances, challenges, and optimization - p. 58 17. 2.5 Disease-modifying and neuroprotective strategies - p. 62 18. 2.6 Emerging technologies and future perspectives - p. 73 19. Chapter 3. Cultural and regional considerations in Parkinson’s pharmacotherapy - p. 97 20. Chapter 4. The tango of Parkinson's treatment: Patients, science and the ryhthm of hope - p. 123 21. Chapter 5. Environmental neurotoxins, circadian rhythms and their pharmacological antagonists in Parkinson's disease - p. 141 22. Chapter 6. Oral bacteriome dysbiosis and mechanisms in cognitive impairment among older people and Parkinson's disease: A systematic review - p. 171 23. Chapter 7. Pharmacokinetics and pharmacodynamics in Parkinson's disease - p. 195 24. Section II. Established pharmacotherapies - p. S2 25. Chapter 8. Dopaminergic treatments for Parkinson's disease: Seeing the unseen - p. 235 26. Chapter 9. Catechol-o-methyl-transferase (COMT) inhibitors: Present problems and relevance of the new ones - p. 265 27. Chapter 10. Non-dopaminergic therapies for Parkinson's disease - p. 275 28. Chapter 11. Management of motor symptoms - p. 289 29. Chapter 12. Non-motor symptoms of parkinson's disease and their pharmacological management - p. 319 30. Chapter 13. Clinical case studies and practical applications - p. 345 31. Section III. Adjunctive and advanced therapies - p. S3 32. Chapter 14. Emergent therapeutic agents in the treatment of Parkinson's disease - p. 363 33. Chapter 15. Future directions in Parkinson's disease pharmacotherapy - p. 391 34. Chapter 16. Pioneering the next generation therapies in Parkinson's disease - p. 427 35. Index - p. 455
